

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT**

Docket Number:
10434/999

Application Number
To Be Assigned

Filing Date
Herewith

Examiner

Art Unit

Invention Title
P53 VACCINE

Inventor(s)
Arnold J. LEVINE


Address to:

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. Except as otherwise indicated, copies of the references are not enclosed since they were previously cited by or submitted to the Patent Office in prior patent application Serial No. 09/946,549, filed September 6, 2001, which is relied upon for an earlier filing date under 35 U.S.C. 120.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: December 12, 2003

By:



Thomas F. Meagher (Reg. No. 29,831)
KENYON & KENYON
One Broadway
New York, New York 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NO. 26646

EV 331382909 US

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT**

Docket Number:

10434/999

Application Number
To Be Assigned

Filing Date
Herewith

Examiner

Art Unit

Invention Title
P53 VACCINE

Inventor(s)
Arnold J. LEVINE


Address to:

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. Except as otherwise indicated, copies of the references are not enclosed since they were previously cited by or submitted to the Patent Office in prior patent application Serial No. 09/946,549, filed September 6, 2001, which is relied upon for an earlier filing date under 35 U.S.C. 120.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: December 12, 2003

By:



Thomas F. Meagher (Reg. No. 29,831)
KENYON & KENYON
One Broadway
New York, New York 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NO. 26646

EV 331382909 US

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Page 1/3

ATTY. DOCKET NO
10434/999

SERIAL NO.
To Be Assigned
APPLICANT

Arnold J. LEVINE

FILING DATE
Herewith

GROUP
Unassigned

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS/ SUBCLA SS	FILING DATE
	5,156,841	October 20, 1992	Rapp	424/88	
	5,693,522	December 2, 1997	Chada et al.	435/2.402	
	5,833,975	November 10, 1998	Paoletti et al.	424/93.2	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS / SUBCL ASS	TRANSLATION	
					YES	NO
	WO 88/06626	September 9, 1988	PCT			
	WO 92/22326	December 23, 1992	PCT			
	WO 93/10814	June 10, 1993	PCT			
	WO 93/24525	December 9, 1993	PCT			
	WO 94/16716	August 4, 1994	PCT			
	EP 475,623	March 18, 1992	EP			

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Kennedy <i>et al.</i> , J. Ex. Med. 161, 1432-1449 (1985)
	Crawford <i>et al.</i> , International Journal of Cancer 30, 403-408 (1982)
	de Fromentel <i>et al.</i> , International Journal of Cancer 39, 195-189 (1987)
	Frey and Levine, Journal of Virology 63, 5440-5444 (1989)
	Levine <i>et al.</i> , Nature 351, 453-456 (1991)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Page 2/3

 ATTY. DOCKET NO.
10434/999

 SERIAL NO.
To Be Assigned

APPLICANT

Arnold J. LEVINE

 FILING DATE
Herewith

 GROUP
Unassigned
Nigro *et al.*, Nature 342, 705-1708 (1989)Culver *et al.*, Proc. Natl. Acad. Sci. USA 88, 3155-3159 (April 1991)Kasid *et al.*, Proc. Natl. Acad. Sci. USA 87, 473-477 (January 1990)Rosenberg *et al.*, The New England Journal of Medicine 323 (9), 570-578 (August 30, 1990)Asher *et al.*, J. Immunology 146 (9), 3227-3234 (May 1, 1991)Kawakami *et al.*, J. Immunology 145 (2), 538-643 (January 15, 1992)Hahn *et al.*, Proc. Natl. Acad. Sci. USA 89, 2679-2683 (April 1992)Curtiss *et al.*, Vaccine 6, 155-160 (1988)Galan *et al.*, Gene 94, 29-35 (1990)Stover, K.S., *et al.*, Vaccines 91, Cold Spring Harbor Laboratory Press, 393-398 (1991)

Hartwell, L., Cell 71, 543-546 (November 13, 1992)

Kastan, M.B. *et al.* Cell 71, 587-597 (November 13, 1992)Snapper, S.B., *et al.*, Proc. Natl. Acad. Sci. USA 85, 6987-6991 (1988)Stover, C.K., *et al.*, Nature 351, 456-460 (1991)Kalpana, B.V., *et al.*, Proc. Natl. Acad. Sci. USA 88, 5433-5437 (1991)Jung *et al.*, Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins, J. Exp. Med. 173, 273-276 (January 1991)Gannon *et al.*, Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form, The EMBO J. 9 (5), 1595-1602 (1990)Chatterjee *et al.*, Idiotype antibody immunotherapy of cancer, Cancer Immunotherapy 38, 75-82 (1994)Boon *et al.*, Toward a genetic analysis of tumor rejection antigens, Adv. in Cancer Res. 58, 177-209 (1992)Boon *et al.*, Tumor antigens recognized by cytolytic T lymphocytes present perspectives for specific immunotherapy, Int. J. Cancer 54, 177-180 (1993)

Ezzell, Cancer Vaccines: an idea whose time has come?, J. of NIH RES. 7, 46-49 (1995)

Coleman *et al.*, Fundamental Immunology, 107 (1989)Houbiers *et al.*, In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild type p53, Eur. J. Immunol. 23, 2072-2077 (1993)Yanuck *et al.*, A mutant p53 tumor suppressor protein is a target for peptide-induced CD8 + cytotoxic T cells, Cancer Res. 53(14), 3257-3261 (1993)

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Page 3/3

ATTY. DOCKET NO.
10434/999SERIAL NO.
To Be Assigned

APPLICANT

Arnold J. LEVINE

FILING DATE
HerewithGROUP
Unassigned

Macatonia et al., *Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro*, J. Exp. Med. **169**, 1255-1264 (April 1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with M.P.E.P. 609; ~~strike out~~ citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

:389039v1